发明名称 Nanocell Drug Delivery System
摘要 Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.
申请公布号 US2015099001(A1) 申请公布日期 2015.04.09
申请号 US201414480123 申请日期 2014.09.08
申请人 Massachusetts Institute of Technology 发明人 Sengupta Shiladitya;Zhao Ganlin;Capila Ishan;Eavarone David;Sasisekharan Ram
分类号 A61K9/51;A61K31/09;A61K47/48;A61K31/704 主分类号 A61K9/51
代理机构 代理人
主权项 1. A nanoparticle comprising a polyester covalently linked to an anti-neoplastic agent, wherein the polyester has a molecular weight of 100-20,000 g/mol, and wherein said nanoparticle 10-1000 nm in its greatest diameter.
地址 Cambridge MA US